Pharmacovigilance: A Pillar of Modern Drug Safety
DOI:
https://doi.org/10.22270/ajprd.v13i5.1626Abstract
Pharmacovigilance (PV) Is A Pivotal Discipline In Clinical Research And Public Health, Focusing On The Detection, Assessment, Understanding, And Prevention Of Adverse Drug Reactions (Adrs). While PV Systems Are Well-Developed In High-Income Countries, They Remain Underdeveloped In Low- And Middle-Income Regions Such As India. This Review Highlights The Historical Evolution, Current Practices, And Future Prospects Of Pharmacovigilance, Emphasizing The Role Of Post-Marketing Surveillance, Risk Management, Patient Safety, And Vaccine Monitoring. It Also Explores Cutting-Edge Developments Including The Integration Of Big Data, Artificial Intelligence, And Pharmacogenomics To Enhance Personalized Medicine And Real-World Evidence Analysis. Despite These Advances, PV Faces Numerous Challenges, Including Under reporting, Poor Data Quality, Regulatory Barriers, Misinformation, Limited Integration Of Real-World Data, And Ethical Concerns Surrounding Data Privacy. The Document Advocates For Robust Policy Support, Capacity Building, Digital Infrastructure Development, And Global Collaboration To Address These Limitations And Ensure Drug Safety Across Diverse Populations.
Downloads
References
Shivamurthi T, Dixit DC, Sri Ramachandra M. Review: Pharmacovigilance and drug safety: A global perspective. Asian J Pharm Res Dev. 2025;13(1):152-60.
Sharma A, Verma U. Adverse drug reaction monitoring: Current scenario in India. Int J Drug Dev Res. 2013;5(3):1-13.
Kumar P, Harugeri A. Role of pharmacovigilance in drug safety system. Perspect Clin Res. 2013;4(1):36-40. doi:10.4103/2229-3485.106398.
Liu R, Zhang P. LP-SDA: Code and datasets for “Towards early detection of adverse drug reactions: Combining pre-clinical drug structures and post-market safety reports” [Computer software]. GitHub; 2019. Available from: https://github.com/ruoqi-liu/L
Herijgers N, Reeder S-J. Risk management plan optimization following implementation of good pharmacovigilance practices Module V (Revision 2): The Janssen experience. Drug Saf. 2021; 44(11):1211-21.
European Medicines Agency. EudraVigilance: EU pharmacovigilance system. In: Wikipedia [Internet]. [cited 2025 Sep 16]. Available from: https://en.wikipedia.org/wiki/EudraVigilance
A review article of clinical research studies and pharmacovigilance for healthcare. Highlights how clinical research underpins pharmacovigilance across the drug lifecycle. 2022.
Jadhav A, Angadi SS, Naiknaware R, Chavhan R. Enhancing patient safety through pharmacovigilance: Effective monitoring and reporting of adverse drug reactions. Int J Creat Res Thoughts. 2024;12(2):IJCRT2402230. Available from: https://ijcrt.org/papers/IJCRT2402230.pdf
Aronson JK. Clinical pharmacology and adverse drug reactions: Understanding mechanisms through pharmacodynamics. Br J Clin Pharmacol. 2010;70(1):3-13.
Rosa C, Faich GA. The evolving role of data sources in pharmacovigilance: From spontaneous reports to electronic health records and literature mining. P T. 2018;43(9):556-62. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117667/
World Health Organization. Module: Adverse events following immunization (AEFI): Monitoring vaccine safety. WHO; 2013. Available from: https://www.who.int/publications/i/item/monitoring-vaccine-safety
Muthusamy K. Artificial intelligence and machine learning in pharmacovigilance: Unlocking potential to drive innovation in patient safety. DIA Glob Forum. 2025.
Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010-21. doi:10.1038/clpt.2012.50.
Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL. Pharmacogenomics. Lancet. 2019;394(10197):521-32.
European Parliament and Council of the European Union. Regulation (EU) 2016/679 (General Data Protection Regulation). Off J Eur Union. 2016;L119.
Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: The science of extrapolation. Blood. 2014;124(22):3191-6.
Hegerius A, Caduff-Janosa P, Savage R, Ellenius J. E-learning in pharmacovigilance: An evaluation of microlearning-based modules developed by the Uppsala Monitoring Centre. Drug Saf. 2020;43:1171-80. doi:10.1007/s40264-020-00981-w.
Bahri P, Tsintis A, Behrman RE, Olsson S, Edwards IR, van Hunsel F. Barriers and enablers to patient reporting of adverse drug reactions: A systematic review. Drug Saf. 2023;46(3):245-59.
Rudrapatna VA, Butte AJ. Opportunities and challenges in using real-world data for health care. J Clin Invest. 2020;130(2):565-74. doi:10.1172/JCI129197.
Makady A, de Boer A, Hillege H, Klungel O, Goettsch W. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858-65.
Kumar P, Khan AM. Challenges and opportunities in pharmacovigilance. J Pharmacol Pharmacother. 2013;4(S1):S39-43.
Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-62. doi:10.1016/S0140-6736(00)02799-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Korade Payal B, Khaire Rahul D, Kathale Ankita A, Sanke Lochani D, Bhandare Tejashwini S, Ghuge Samiksha K
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 